New hope for tumors that beat immunotherapy? early trial launches
Disease control
Recruiting now
This early-phase study tests a new drug (PLN-101095) alone or with pembrolizumab in adults whose advanced solid tumors have stopped responding to standard immunotherapy. About 124 participants will receive the treatment to check safety and early signs of tumor shrinkage. The goal…
Phase: PHASE1 • Sponsor: Pliant Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC